Loading stock data…
MacroGenics, Inc. (MGNX)
$4.86+0.05 (+1.04%)
After Hours$4.86+0.00 (+0.00%)· Last close Jun 29
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MacroGenics, Inc. in the Healthcare sector is trading at $4.86 with a market capitalization of $267M. Wall Street consensus targets $6.75 (4 analysts), implying a +38.9% move over the next 12 months. The stock is currently near its 52-week high of $5.08, remaining 100.8% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +38.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $20.77M↓ | $41.23M↓ | $72.84M↑ | $22.24M↑ | $13.19M |
| Gross Profit | $11.24M↓ | $31.11M↓ | $61.25M↑ | $13.34M↑ | $7.79M |
| Operating Income | -$33.44M↓ | -$12.10M↓ | $18.64M↑ | -$36.76M↑ | -$42.62M |
| Net Income | -$36.77M↓ | -$14.15M↓ | $16.82M↑ | -$36.25M↑ | -$41.04M |
Peer Comparison
JNJUNHPFE
Fundamentals
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$266.97M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-331.91%
Volume
Today's trading volume
1.35M
Recent News
Sanofi Wins FDA Nod for Expanded Use of T1D Drug in Children
SNY wins FDA approval to expand Tzield's use in children with newly diagnosed stage 3 T1D, opening treatment to a broader patient group.
How The MacroGenics (MGNX) Story Is Shifting With ADC Pipeline Bets And 2026 Data Risks
MacroGenics is back in focus after bullish analysts raised price targets by about US$1 to US$2, including one move from US$3 to US$4 tied to the company’s recent Q4 update. These shifts are closely linked to Street commentary around the antibody drug conjugate pipeline, upcoming data expected in 2026, and reactions to the Tubulus deal and recent corporate activity. As you read on, you will see how these evolving targets fit into the broader analyst narrative and what to watch next. Wall...
Akari Therapeutics Highlights 1st ASCO Abstract Acceptance
By Karen Roman Akari Therapeutics, Plc (Nasdaq: AKTX) said President and CEO Abizer Gaslightwala was part of a Virtual Investor “What This Means” interview highlighting the company’s first abstract acceptance […]
VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC
By Karen Roman VERAXA Biotech AG said it has a securities purchase agreement with an institutional investor for $27.5 million, separate to a $50 million share purchase agreement with Lincoln Park Capital Fund. The company also applied for a Nasdaq listing under the ticker symbol “VRXA” via a combination with Voyager Acquisition Corp. (Nasdaq: VACH) […] The post VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC appeared first on ExecEdge.
MacroGenics Eyes $200M Cash Boost, 2028 Runway Ahead of Cancer Pipeline Updates
MacroGenics (NASDAQ:MGNX) Chief Executive Officer Eric Risser said the biotechnology company has strengthened its balance sheet through two recent transactions while preparing for a series of clinical updates across its oncology pipeline. Speaking during an informal discussion hosted by Stifel seni